Abstract Search

ea0090p139 | Pituitary and Neuroendocrinology | ECE2023

Patients with acromegaly continue to derive clinical benefit from pasireotide long-acting release (LAR) for up to 12 years of treatment: Follow-up analysis of patients who received pasireotide during the clinical trial programme

Gadelha Monica , Grineva Elena , Miguel Escalante Pulido Jesus , Rollin Guilherme , Leelawattana Rattana , De Block Christophe , Piacentini Andrea , Schmidt Fabian , Pedroncelli Alberto M , Kapoor Nitin

Introduction: Acromegaly is associated with significant morbidity and reduced quality of life. A robust clinical programme (14 trials) established pasireotide as an effective second-generation somatostatin receptor ligand for the treatment of various endocrine conditions, including acromegaly. Patients who completed a previous pasireotide trial and continued to receive clinical benefit, according to the parent study investigator, could continue treatment in the B2412 rollover ...

3 shares

ea0090p682 | Pituitary and Neuroendocrinology | ECE2023

A rollover study for patients who continued to receive benefit from pasireotide at completion of an earlier trial (B2412): An 8-year interim analysis

Gadelha Monica , Bronstein Marcello , Grineva Elena , Kapoor Nitin , De Block Christophe , Miguel Escalante Pulido Jesus , Rollin Guilherme , Baggenstoss Rejane , Piacentini Andrea , Pedroncelli Alberto , Gallardo Wilson

Introduction: A robust clinical programme of 14 trials demonstrated pasireotide as an effective treatment for patients with rare endocrine disorders, including acromegaly and Cushings disease (CD). Patients with acromegaly or CD have significant morbidity, reduced quality of life and, if inadequately treated, higher mortality risk than the general population. This 8-year interim analysis evaluated long-term safety of pasireotide treatment in patients with acromegaly, CD ...

0 shares

Endocrine Abstracts

Patients with acromegaly continue to derive clinical benefit from pasireotide long-acting release (LAR) for up to 12 years of treatment: Follow-up analysis of patients who received pasireotide during the clinical trial programme

A rollover study for patients who continued to receive benefit from pasireotide at completion of an earlier trial (B2412): An 8-year interim analysis

BiosciAbstracts